These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 18165622

  • 1. Review: side effects of approved molecular targeted therapies in solid cancers.
    Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A.
    Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
    [Abstract] [Full Text] [Related]

  • 2. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
    de Castro G, Awada A.
    Curr Opin Oncol; 2006 Jul; 18(4):307-15. PubMed ID: 16721122
    [Abstract] [Full Text] [Related]

  • 3. Molecular targeted therapies for solid tumors: management of side effects.
    Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.
    Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
    [Abstract] [Full Text] [Related]

  • 4. Targeted therapies: a new generation of cancer treatments.
    Gerber DE.
    Am Fam Physician; 2008 Feb 01; 77(3):311-9. PubMed ID: 18297955
    [Abstract] [Full Text] [Related]

  • 5. Targeted therapies: aiming for the bull's-eye.
    Gaguski ME.
    ONS Connect; 2007 Jul 01; 22(7):8-12. PubMed ID: 17694778
    [No Abstract] [Full Text] [Related]

  • 6. Targeted therapies: a nursing perspective.
    Kay P.
    Semin Oncol Nurs; 2006 Feb 01; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [Abstract] [Full Text] [Related]

  • 7. Overview of targeted therapies in oncology.
    Kalyn R.
    J Oncol Pharm Pract; 2007 Dec 01; 13(4):199-205. PubMed ID: 18045779
    [Abstract] [Full Text] [Related]

  • 8. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD, Moehler M.
    Curr Opin Oncol; 2009 Jul 01; 21(4):381-5. PubMed ID: 19412098
    [Abstract] [Full Text] [Related]

  • 9. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA.
    Dermatol Clin; 2008 Jan 01; 26(1):121-59, ix. PubMed ID: 18023775
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME.
    Oncologist; 2007 May 01; 12(5):610-21. PubMed ID: 17522250
    [Abstract] [Full Text] [Related]

  • 11. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
    Esper P, Gale D, Muehlbauer P.
    Clin J Oncol Nurs; 2007 Oct 01; 11(5):659-66. PubMed ID: 17962174
    [Abstract] [Full Text] [Related]

  • 12. Future strategies for targeted therapies and tailored patient management in pancreatic cancer.
    Ko AH.
    Semin Oncol; 2007 Aug 01; 34(4):354-64. PubMed ID: 17674964
    [Abstract] [Full Text] [Related]

  • 13. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
    Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C.
    Eur J Cancer; 2009 Sep 01; 45 Suppl 1():309-17. PubMed ID: 19775627
    [No Abstract] [Full Text] [Related]

  • 14. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G, Ciardiello F, Gasparini G.
    Nat Clin Pract Oncol; 2008 Sep 01; 5(9):521-30. PubMed ID: 18594498
    [Abstract] [Full Text] [Related]

  • 15. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.
    Clin Cancer Res; 2009 Apr 01; 15(7):2552-8. PubMed ID: 19318484
    [Abstract] [Full Text] [Related]

  • 16. ErbB family targeting.
    Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK.
    Curr Opin Investig Drugs; 2003 Dec 01; 4(12):1451-4. PubMed ID: 14763131
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, Delattre JY.
    Oncologist; 2008 Sep 01; 13(9):978-92. PubMed ID: 18779539
    [Abstract] [Full Text] [Related]

  • 18. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):675-702. PubMed ID: 19525314
    [Abstract] [Full Text] [Related]

  • 19. Skin reactions to the new biologic anticancer drugs.
    Myskowski PL, Halpern AC.
    Curr Opin Support Palliat Care; 2009 Dec 01; 3(4):294-9. PubMed ID: 19797958
    [Abstract] [Full Text] [Related]

  • 20. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.
    Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Perez-Garcia J, Tabernero J.
    Curr Opin Oncol; 2009 Jul 01; 21(4):374-80. PubMed ID: 19412097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.